SGX Pharmaceuticals to Host Research & Development Luncheon
SAN DIEGO, Feb. 8 /PRNewswire-FirstCall/ — SGX Pharmaceuticals, Inc. will be hosting a Research & Development Luncheon on Thursday, February 15, 2007 from 11:30 a.m. to 1:00 p.m. Eastern Time at the Waldorf=Astoria Hotel in New York City to update analysts and investors on the Company’s oncology pipeline. The program will feature Michael S. Gordon, M.D., a renowned expert on the MET tyrosine kinase and Associate Director of Research for the Arizona Cancer Center, to provide a clinical perspective of the MET pathway and opportunities for the development of inhibitors of this drug target.
The agenda for the R&D Luncheon includes: 11:00am EDT Registration 11:30am EDT Introduction and Corporate Overview Mike Grey, President and Chief Executive Officer, SGX Pharmaceuticals BCR-ABL Development Plans Terry Rugg, M.D., Chief Medical Officer, SGX Pharmaceuticals SGX Drug Discovery Pipeline, including MET development candidate SGX523 and JAK2 inhibitors Stephen Burley, M.D., D.Phil., Chief Scientific Officer, SGX Pharmaceuticals Guest Commentary: MET Pathway: A key cancer control target Michael S. Gordon, M.D. Associate Director of Clinical Research, Arizona Cancer Center Associate Professor of Clinical Medicine, University of Arizona College of Medicine President, Premiere Oncology of Arizona, Scottsdale, AZ
A live webcast of the presentation will be available under the investor relations section of the Company’s website at http://www.sgxpharma.com/. Replays of the presentation will be available for 90 days following the event. Please connect to the Company’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About SGX Pharmaceuticals
SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. SGX’s oncology pipeline includes drug candidates from its enabling, proprietary FAST(TM) drug discovery platform, such as next generation BCR-ABL inhibitors currently being developed in partnership with Novartis, MET tyrosine kinase inhibitors including SGX523, and a series of orally bioavailable JAK2 inhibitors. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com/ and in the Company’s various filings with the Securities and Exchange Commission.
SGX Pharmaceuticals, Inc.
CONTACT: Todd Myers, Chief Financial Officer of SGX Pharmaceuticals,Inc., +1-858-558-4850; or Media & Investor Relations, Jason Spark of PorterNovelli Life Sciences, +1-619-849-6005, for SGX Pharmaceuticals, Inc.